61 / 74 · 0:51 · Original AXON film
NMN
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
NMN | NAD+ precursor
NMN, nicotinamide mononucleotide, is a precursor used in NAD+ metabolism. It is a small molecule, and its evidence should remain separate from peptide research. [1]
HUMAN TRIAL | Specific population
A ten-week randomized trial studied postmenopausal women with prediabetes who had overweight or obesity. The study examined specific metabolic outcomes rather than lifespan. [1]
Measured: muscle insulin sensitivity
Researchers reported improved muscle insulin sensitivity with NMN, while body composition did not change. A physiological measurement and a visible body transformation are different outcomes. [1]
Limits: study size and duration
This small, short study cannot settle long-term health benefits or safety. Its findings should not be generalized to everyone or described as proven anti-aging. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Yoshino et al. (2021): Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women →Ten-week study in postmenopausal women with prediabetes; muscle insulin sensitivity findings and no body-composition change.
